Description
Eltrombopag is a prescription drug which is used under the guidance of the doctor.
Eltrombopag drug may be used as part of combination therapy. Thereby drug may need to take it with other medications.
Indication
Eltrombopag is mainly indicated for the treatment of patients having :
• Reduced platelet levels due to chronic immune thrombocytopenia
• Reduced platelet counts due to chronic hepatitis C virus infection
• Severe Aplastic Anemia :
• First line treatment of severe Aplastic Anemia
• Treatment of refractory severe Aplastic Anemia.
Mechanism Of Action
Eltrombopag be part of a class of drugs called thrombopoietin (TPO) receptor agonists. Classification of drugs is an association of medications which work in a similar way. These drugs are often used to treat similar conditions. Eltrombopag works by raise cells in bone marrow and leads these cells to make various platelets. This effect reduces the risk of bleeding.
Dosage and administration
Chronic Immune Thrombocytopenia:
Indicated only in patients with chronic immune thrombocytopenia whose clinical condition increases bleeding risk
First-line therapy:
Concomitant use with standard immunosuppressive therapy, for patients with serious aplastic Anemia (SAA)
Usual dose:
150 mg PO qDay for 6 months
Do not give more than starting dose; total duration is 6 months
Common Side Effects
• low red blood cells
• nausea
• fever
• weakness
• pain in head
• cough
• decreased appetite
• flu
• diarrhea
Precautions
The drug causes warning condition, call the doctor while new medication interaction
Disease progression warning: Avoid using the drug while the patients have myelodysplastic syndrome (MDS), will increase the risk of death.
If other blood clot risk factors, then avoid the drug because it will increase platelet counts and blood clots.
If the patients have cataracts, avoid the drug due to the drug effects cataracts and make the condition worse.
Drug Interaction
Eltrombopag interaction with these drugs ezetimibe, glyburide, Olmesartan, repaglinide, valsartan, imatinib, irinotecan, lapatinib, methotrexate, mitoxantrone, Bosentan, sulfasalazine, and topotecan irinotecan leads an increase of side effects. hence the doctor may reduce the dosage of these drugs if required.
Eltrombopag co-administration with Cholesterol-reducing drugs like atorvastatin, fluvastatin, rosuvastatin, pravastatin, and simvastatin, pitavastatin. Have high side effects can contain muscle pain. The doctor may reduce the dosage of your cholesterol drugs.
Lactation
The presence of Eltrombopag or metabolites in human milk, the drug has possible serious side effects for the breastfed child. The drug is not recommended during breastfeeding
Pregnancy
Pregnancy category is C
Use the Eltrombopag with caution if asset outweighs risks. Animal studies reveal risk and human studies not available or neither animal nor human studies done.
Storage
Store at room temperature 20°C to 25°C.
Discard the left-out medicine if not used within 30 minutes
Missed Dose
In case of a missed dose, patients must consult with a medical practitioner and follow the instructions given by them. thereby missed dose should be avoided and follow the regular dosing schedule.
FOR MORE INFORMATION:
EMAIL:
PHONE:
91- 9987711567
This content is written very well. Your use of formatting when making your points makes your observations very clear and easy to understand. Thank you.
ReplyDeletebuy ecstasy online
онкология I think this is an informative post and it is very useful and knowledgeable. therefore, I would like to thank you for the efforts you have made in writing this article.
ReplyDelete